Dermoval

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dermoval

What is Dermoval? Defining Clobetasol Propionate

Property Description
Active ingredient Clobetasol propionate
Forms Cream, ointment, solution
Pharmacological class Super-potent topical corticosteroid
Origin Synthetic glucocorticoid
Route Topical application

Dermoval is a prescription brand name medication primarily containing Clobetasol propionate as its sole active ingredient. This substance is chemically classified as a fluorinated corticosteroid, which is a type of synthetic glucocorticoid used only for localized treatment on the skin. Its identity is fundamentally linked to its design as a synthetic analog of naturally occurring hormones, manufactured to possess powerful dermatological activity.


Class and Potency: Understanding the Super-Potent Topical Category

This medication is categorized as a super-potent topical corticosteroid, representing the highest potency classification available in its class. This power is clinically recognized for its substantial anti-inflammatory and vasoconstrictive capability compared to lower-strength corticosteroids. Clobetasol propionate is a potent vasoconstrictor, which contributes significantly to its high anti-inflammatory action. The patient-friendly conclusion from this is that the medicine is designed to very rapidly reduce swelling and redness in the affected area.

Its general purpose is the rapid and intensive action required to manage severe, chronic, or recalcitrant inflammatory skin conditions, such as persistent forms of psoriasis or difficult eczema. This strength indicates the medicine is specifically reserved for persistent or intense skin issues that do not respond sufficiently to milder treatments.


Composition and Forms: The Cream, Ointment, and Solution Basis

Dermoval is formulated as a single-ingredient product and is available in various dosage forms, including a cream, a heavier ointment, and a specialized solution intended primarily for the scalp. Each form combines the active Clobetasol propionate with a specific base or vehicle, such as an emulsifying cream base or a lipid/petroleum base. These differing compositions ensure that the medicine can be effectively delivered to various tissue types and anatomical locations for localized and efficient relief via topical application.

Regulatory References

  1. DailyMed (Clobetasol Propionate Prescribing Information)

What side effects are possible with Dermoval?

Possible side effects and safety information

The safety profile of Dermoval (Clobetasol Propionate), a super-potent topical corticosteroid, is structured by regulatory authorities based on local application site reactions and the potential for systemic absorption.

Common Adverse Reactions

Adverse effects listed as common (1% incidence in regulatory sources) typically involve the application site, including a burning or stinging sensation, pruritus (itching), irritation, erythema (redness), and folliculitis. These local reactions are most frequently reported at the start of treatment.


Serious and Systemic Adverse Reactions

Due to the drug's high potency, significant systemic absorption can lead to serious adverse reactions, particularly with extensive or prolonged use. These effects are officially documented as Endocrine disorders and Eye disorders in System-Organ-Classes (SOC).

  • Endocrine: Manifestations of Cushing's syndrome and the potential for Hypothalamic-Pituitary-Adrenal (HPA) axis suppression.
  • Ophthalmic: Complications such as glaucoma and cataracts are reported in association with topical corticosteroid use.

Duration and Population-Specific Safety

Local adverse reactions like skin atrophy (thinning), striae (stretch marks), and telangiectasia (spider veins) are primarily associated with prolonged use. Pediatric patients are officially noted as being more susceptible to systemic toxicity, including HPA axis suppression, due to their larger skin surface area to body mass ratio.

Regulatory labeling establishes clear restrictions, stating that Clobetasol Propionate should not be used for rosacea or perioral dermatitis, and its application should be avoided on areas like the face, groin, or axillae.

Overdose and Emergency Response

Dermoval (clobetasol propionate) is a potent topical corticosteroid, and using more than the prescribed amount, applying it over large areas, or using it for a prolonged period can lead to serious systemic effects due to increased absorption into the bloodstream. While a sudden, acute overdose from external use is rare, chronic overuse is a greater concern.

Potential Overdose Symptoms

Chronic excessive use can lead to hypercortisolism, known as Cushing's syndrome, and reversible suppression of the hypothalamic-pituitary-adrenal (HPA) axis, which affects the body's natural production of steroid hormones. Signs of systemic absorption and potential overdose include:

Systemic Manifestation Key Symptoms
HPA Axis Suppression Unusual fatigue, muscle weakness, low blood pressure.
Cushing's Syndrome Rounded face, central obesity, elevated blood pressure, high blood sugar (with increased thirst/urination).
Local Effects (Long-term) Severe skin thinning, stretch marks (striae), easy bruising, skin color changes, and worsening of certain skin conditions.

When to Seek Immediate Help

Contact a healthcare professional or seek emergency medical attention immediately if you or someone else experiences:

  • Signs of a severe allergic reaction, such as swelling of the face, tongue, or throat, hives, or difficulty breathing.
  • Any rapid onset of severe systemic symptoms from the table above.
  • Accidental ingestion of the medication.

Never exceed the prescribed dose or duration of use for Dermoval. The maximum weekly dose should generally not exceed 50 grams for adults. If a dose is missed, apply it as soon as you remember, unless it is almost time for your next dose; do not double the amount.

Therapeutic Uses of Dermoval

Dermoval (Clobetasol Propionate) is a highly potent topical therapy generally reserved for providing symptomatic support in challenging skin conditions. The medication is used for the management of symptoms related to inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. It is applied across domains involving heightened, disruptive skin inflammation.

It is commonly used across conditions characterized by periods of heightened symptoms and activity, such as chronic plaque psoriasis, recurrent atopic dermatitis (eczema), and Lichen Sclerosus.

The medication is relevant when symptoms become more noticeable and short-term symptomatic assistance is needed. It plays a role in managing symptoms during periods of heightened activity and contributing to improved comfort during symptomatic periods.

“This medication is applied when symptoms such as pruritus (itching), redness (erythema), and scaling may create noticeable physiological strain.”

It is used for managing these distressing symptoms, offering supportive relief that helps patients cope more steadily with difficult episodes and assists with maintaining functional stability.


Quick Fact: Relief for Inflammation and Itching Dermoval is generally considered relevant for symptom management in recalcitrant dermatoses that require focused therapeutic support.

Eligibility and Restrictions for Use

Eligibility for Dermoval (Clobetasol Propionate)

The official eligibility profile for Dermoval is defined by strict regulatory constraints that categorize who can and cannot use this super-potent topical corticosteroid.

Contraindicated Populations Official Restriction
Known Hypersensitivity Patients with a history of allergy to any component must not use the medicine.
Infants/Young Children Contraindicated in children under one year of age; use not recommended in children under 12.
Infectious Conditions Contraindicated for use on untreated cutaneous infections (viral, fungal, bacterial).

Condition-Specific Non-Eligibility The regulatory label strictly prohibits use for certain dermatological conditions, including rosacea, perioral dermatitis, acne vulgaris, and pruritus without inflammation. Application to the face, groin, or armpits is also generally restricted or not recommended.

Conditional Use For pregnant or breastfeeding individuals, use is conditional and should only be considered if the potential benefit justifies the potential risk, as safety has not been established.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Dermoval (clobetasol propionate) is a potent topical corticosteroid. While systemic absorption is generally low, clinically significant drug interactions can occur when co-administered with certain medicines, particularly those that inhibit the body's metabolism of corticosteroids.


Documented Interactions

Interactions are primarily related to medicinal products that inhibit the Cytochrome P450 3A4 (CYP3A4) enzyme system. This system is responsible for the metabolism and clearance of the absorbed corticosteroid. Inhibition of this enzyme can lead to increased systemic exposure to clobetasol propionate, potentially resulting in systemic corticosteroid effects.

Interacting Product Category Specific Examples Cited Regulatory Constraint/Requirement
Potent CYP3A4 Inhibitors Ritonavir, Itraconazole Avoid co-administration unless the potential benefit outweighs the increased risk of systemic side effects.

If co-administration is necessary, the official regulatory requirement is that the patient must be monitored for signs and symptoms of systemic corticosteroid side effects, such as the suppression of the hypothalamic-pituitary-adrenal (HPA) axis.


Contextual Constraints

The risk of these drug interactions is heightened by factors that increase the drug's systemic absorption. This includes prolonged use, application to large surface areas, and the use of occlusive dressings. These conditions increase the amount of clobetasol propionate available to interact with co-administered CYP3A4 inhibitors.

Mechanism of Action

Pharmacodynamic Mechanism of Action

Dermoval (clobetasol propionate) acts as a high-affinity agonist for the intracellular Cytosolic Glucocorticoid Receptor (GR). This activated complex translocates to the nucleus, initiating transcriptional modulation by promoting the expression of anti-inflammatory proteins, such as Annexin A1, and simultaneously inhibiting pro-inflammatory transcription factors like NF-kappaB.

This molecular cascade leads to the inhibition of the enzyme Phospholipase A2 ( PLA2) by Annexin A1. Blocking PLA2 prevents the release of arachidonic acid from cell membranes, thereby suppressing the synthesis of subsequent inflammatory mediators including prostaglandins and leukotrienes.

At the tissue level, the mechanism causes localized vasoconstriction which limits blood flow and erythema. Furthermore, the mechanism exerts an antiproliferative effect by modulating the rate of keratinocyte growth in the target tissue.

Dosage and Administration Information

How Dermoval is Used

Dermoval, which contains Clobetasol Propionate 0.05%, is strictly administered via the topical/cutaneous route for localized treatment of the skin, and is not intended for internal, oral, or ophthalmic use. The standard application model is defined by its potency, strict dose limits, and short-term duration.


Administration Schedule and Limits

Element Official Guideline
Route of Administration Topical/Cutaneous application only.
Standard Frequency Twice daily (BID) for most forms (cream, ointment, etc.) or once daily (QD) for shampoo.
Dosing Limit The total applied dose must not exceed 50 grams (or 50 mL) per week to control systemic exposure.

The majority of formulations, such as the cream and ointment, are applied as a thin layer and gently rubbed into the affected skin areas. The Clobetasol Propionate shampoo formulation, intended for the scalp, must be applied to the dry scalp and left in place for 15 minutes before rinsing.

Course Duration and Restrictions

Due to the medication’s high potency, the initial treatment is generally limited to two consecutive weeks for most conditions. For certain severe, difficult-to-treat skin conditions, treatment may be conditionally extended up to a maximum of four consecutive weeks, provided the weekly dose ceiling is not surpassed.

Application Constraints: Instructions prohibit use on the face, groin, or axillae (armpits). Additionally, the treated area should not be covered or wrapped with occlusive dressings unless explicitly directed, as this increases drug absorption. Upon achieving control, the protocol advises a gradual discontinuation or transition to a less potent agent.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Dermoval


Evidence for Use in Plaque Psoriasis

The research base where clobetasol propionate was studied for plaque psoriasis primarily consists of short-term Randomized Controlled Trials (RCTs) and summaries of these trials called meta-analyses. These studies were used in research exploring how symptoms change over time in Adults and Adolescents (aged 16 and older) diagnosed with moderate to severe plaque-type psoriasis. The research monitored outcomes such as overall disease severity and specific clinical signs, including scaling, redness, and plaque thickness.

The studies report how symptoms evolved in the observed populations following the short treatment periods, typically lasting only two to four weeks. Data show patterns related to how symptoms evolved in the observed populations. What remains uncertain is the long-term management of the condition. Follow-up durations were limited in these core studies, meaning data for long-term outcomes and recurrence patterns after the medicine is stopped are not well characterized.


Evidence for Use in Atopic Dermatitis and Eczema

For conditions like atopic dermatitis (eczema), the evidence was evaluated in controlled clinical trials. This research explored short-term symptom changes in populations of Adults and Adolescents (typically 12 years and older) who had been diagnosed with moderate to severe eczema. Studies monitored outcomes capturing phases of heightened symptom activity, such as the degree of inflammation, and patient-reported outcomes describing perceived discomfort.

Research highlights changes measured during the study period, contributing to understanding symptom patterns. Long-term effects are not fully established regarding the frequency of disease flare-ups or the long-term need for additional treatments after the study period ends. Additionally, data for certain groups remain insufficient, especially for children under the age of 12.


What Remains Uncertain About the Evidence

Despite numerous studies, the evidence highlights several areas where research is ongoing and certainty remains low. Long-term effects are not fully established for any of the conditions studied, as the majority of trials were short-term. Evidence quality varies across studies, and comparative evidence is lacking for how this medicine performs against many alternative long-term management strategies. The existing studies provide context but not individual predictions.

Key Studies & References Label: CLOBETASOL PROPIONATE cream (FDA/DailyMed)

Frequently Asked Questions (FAQ)

Common questions about Dermoval (FAQ)

Q: How quickly does Dermoval usually start working?

Studies and official information indicate that the medicine is designed for rapid and intensive anti-inflammatory action. The efficacy of the medicine is typically assessed by monitoring symptom change over the initial short-term course of treatment specified in the regulatory guidelines.


Q: Can Dermoval be used for general redness or irritation?

Official regulatory documents strictly contraindicate the use of this potent medicine for general conditions such as rosacea and perioral dermatitis. The official label also explicitly prohibits its use for pruritus (itching) that occurs without inflammation.


Q: Is Dermoval safe for use in children?

Regulatory labeling states the medicine is contraindicated for use in children under one year of age and is generally not recommended for children under 12. Official sources note that children are more susceptible to systemic toxicity, such as HPA axis suppression, due to their body composition.


Q: What happens if I stop using Dermoval suddenly?

Official guidance advises that application should be gradually discontinued or a less potent medicine substituted after the condition is controlled. Abrupt cessation of potent corticosteroids may result in a recurrence or worsening of the pre-existing dermatoses.


Q: Does Dermoval interact with common over-the-counter pain relievers?

Regulatory documents primarily describe interactions with potent CYP3A4 inhibitors (such as certain antifungal or HIV medicines), which can increase the risk of systemic effects. Common over-the-counter pain relievers are generally not classified as these specific types of potent inhibitors.


Q: What is the difference between Dermoval cream and ointment?

The difference lies primarily in the base composition. The ointment formulation uses a lipid/petroleum base, which is generally heavier and more occlusive (it blocks moisture) than the cream formulation, which uses an emulsifying base. The choice between forms is often related to the target skin area or condition.


Q: Do Dermoval side effects go away when you stop using it?

Common local reactions often resolve upon discontinuation of the medicine. However, official information notes that certain local adverse effects, such as skin atrophy (thinning) and striae (stretch marks), are primarily associated with prolonged use and may be irreversible.


Q: What should I do if I accidentally get Dermoval in my eyes?

Official prescribing information includes a warning that the medicine is not for ophthalmic use. Regulatory guidance suggests that in case of accidental contact, rinsing the affected eye area thoroughly with water is generally recommended.


Q: Is there a generic version of Dermoval available?

Dermoval is a brand name for the active ingredient Clobetasol Propionate 0.05%. This specific compound is the generic name for the medicine. Generic formulations containing Clobetasol Propionate may be available from various manufacturers.


Q: Is Dermoval absorbed into the bloodstream?

The medicine can be absorbed through the skin, leading to systemic exposure of Clobetasol Propionate in the bloodstream. While this is generally low, the risk of systemic effects like HPA axis suppression is tied to the amount absorbed.


Q: Why do doctors prescribe Dermoval for such short periods?

The treatment duration is strictly limited (e.g., to two consecutive weeks) because the medicine is classified as a super-potent corticosteroid. Official guidance requires this limitation to minimize the risk of significant systemic absorption and potential effects such as HPA axis suppression.


Q: Can Dermoval cause changes in skin color?

Regulatory documents list certain types of pigmentation changes as a possible local adverse reaction. Specifically, hypopigmentation (lightening of the skin) is noted in official reports.


Q: Is Dermoval effective for treating severe itching?

Dermoval is indicated for treating severe inflammatory skin conditions where itching (pruritus) is a primary symptom, such as in psoriasis or eczema. Its potent anti-inflammatory effects are designed to address the underlying cause of the severe itching associated with these conditions.


Q: Can Dermoval be used on areas with broken skin?

Official documents warn against applying the medicine to areas of the skin where the barrier is compromised, such as widespread weeping or abraded skin. This is due to the potential for increased systemic absorption of the potent medicine.


Q: What is the risk profile of Dermoval compared to weaker topical steroids?

Dermoval is in the super-potent (Class I) category, the highest potency classification. Regulatory warnings indicate that the risk of systemic effects and local skin atrophy is noted to be higher compared to lower-potency topical corticosteroids.


Q: What does 'topical corticosteroid' actually mean?

A corticosteroid is a synthetic medicine that mimics the natural hormone cortisol, and topical indicates that the medicine is designed for localized application to the surface of the skin. Its purpose is to reduce inflammation and suppress certain immune responses locally.


Q: Is Dermoval known to cause rebound symptoms after stopping treatment?

While the term 'rebound' is not always explicitly used, regulatory guidance advises gradual discontinuation to avoid recurrence. This is due to the potential for the original condition to return or worsen if the application is stopped abruptly.


Q: Does the time of day matter when applying Dermoval?

The medicine is typically prescribed for application twice daily (BID). Adhering to the recommended dosage frequency and ensuring the application intervals are consistently spaced throughout the day is the critical factor for maintaining steady control of symptoms.


Q: What is the difference in potency between different Dermoval formats (e.g., lotion vs. cream)?

All formulations (cream, ointment, solution, lotion) contain the same concentration of the active ingredient (Clobetasol Propionate 0.05%). Regulatory authorities therefore assign the same super-potent classification to all these formats.


Q: Are there any specific foods or drinks to avoid while using Dermoval?

Regulatory labeling does not contain any warnings or restrictions regarding the consumption of specific foods or non-alcoholic beverages while using this medicine.


Q: Can Dermoval affect blood sugar levels?

Due to the potential for systemic absorption and resulting endocrine effects (HPA axis suppression), blood sugar levels may be monitored in patients who have pre-existing conditions. This is a potential systemic effect, although it is not consistently noted as a common side effect.


Q: Does sun exposure make Dermoval use less safe?

Official regulatory documentation does not specifically list sun exposure or photosensitivity as a special warning or precaution when using this medicine.


Q: Can I use other skin creams or moisturizers with Dermoval?

Regulatory documents do not list any specific restrictions regarding the concurrent use of standard, non-medicated moisturizers. The use of occlusive dressings is restricted, but this typically does not apply to non-occlusive moisturizers.


Q: Does Dermoval have any known interaction with alcohol?

Regulatory documents do not list any known drug interaction between topical Clobetasol Propionate and the consumption of alcohol.


Q: Can Dermoval cause problems with wound healing?

The medicine's mechanism of action includes an antiproliferative effect, which is related to cell growth. For this reason, official guidance generally warns against use on open wounds or ulcers due to the risk of systemic absorption and the potential impact on skin growth processes.


Q: What if I forget to apply a dose of Dermoval?

Standard regulatory guidance addresses a missed dose by suggesting it be applied as soon as a person remembers, unless it is nearly time for the next scheduled dose. If it is nearly time for the next dose, the missed dose should be skipped, and the dose should not be doubled.


Q: Are there any common interactions between Dermoval and supplements?

Regulatory documents list interactions primarily with medicinal CYP3A4 inhibitors. There is no specific warning or restriction regarding the concurrent use of general dietary or herbal supplements.


Q: Is Dermoval used for lichen planus?

Regulatory indications often include specific inflammatory skin conditions in addition to psoriasis and eczema. Official documents commonly list Lichen Planus as one of the specific recalcitrant dermatoses for which the medicine may be indicated to treat.


Q: Do patients commonly report weight gain as a side effect of Dermoval?

The potential for Cushing's syndrome is documented as a serious systemic adverse reaction. Since rapid weight gain is a known manifestation of Cushing's syndrome, it is indirectly linked to the drug's potential serious systemic effects following significant absorption.


Q: Does Dermoval affect blood pressure?

Due to the potential for systemic absorption and resulting endocrine effects, symptoms of Cushing's syndrome may be observed. High blood pressure (hypertension) is noted as a known manifestation of Cushing's syndrome.

How should Dermoval be stored and disposed of?

How to Store and Dispose of Dermoval (Clobetasol Propionate)

Official regulatory guidelines require the storage of Dermoval to maintain its stability and ensure safety.

Storage Requirements

Condition Regulatory Mandate
Temperature Store at controlled room temperature, typically 15^circC to 30^circC (59^circF to 86^circF).
Prohibitions Do not freeze and do not refrigerate the cream or lotion formulations.
Safety Must be kept out of the reach of children.
Stability For some creams, discard any unused product after 2 weeks of opening.

Disposal Requirements

Unused or expired Dermoval must be disposed of in accordance with federal, state, and local regulations. Do not discard the medicine in household trash or pour it down a sink or toilet; instead, it should be returned to a pharmacist for proper management as pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dermoval found in:

A-Z Index: